1D-LSD, also known as 1-(1,2-dimethylcyclobutane-1-carbonyl)-LSD or as SYN-L-229, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is believed to be a prodrug of LSD and replaced 1V-LSD in Germany after 1V-LSD became covered by the German NpSG law in 2022.
1D-LSD has a dose of 10 to 350üg depending on the intended use, with blotter tabs typically containing 150üg. It is said to be roughly comparable in potency to 1V-LSD. 1D-LSD is said to have a much faster onset than 1V-LSD or LSD but to also have a shorter duration in comparison (6âÂÂ8hours and 10âÂÂ12hours, respectively).
Analogues of 1D-LSD include ALD-52 (1A-LSD), 1P-LSD, 1S-LSD, 1DD-LSD, 1V-LSD, 1cP-LSD, and 1T-LSD, among others.
1D-LSD was encountered online as a novel designer drug in October 2022 after 1V-LSD was prohibited in Germany in September 2022.
According to the current legal situation, 1D-LSD is neither explicitly mentioned in the Narcotic Drugs Ordinance nor in the Psychotropic Substances Ordinance (SV/PV), thus it is neither to be classified as a narcotic drug in the sense of the SV nor as a psychotropic substance in the sense of the PV.
1D-LSD is not a controlled substance in Canada as of 2025.
Since the 14 June 2024 1D-LSD (and 1T-LSD) are covered by the German NpSG law.
1D-LSD is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.